These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 23670856)

  • 1. Substrate versus inhibitor dynamics of P-glycoprotein.
    Ma J; Biggin PC
    Proteins; 2013 Sep; 81(9):1653-68. PubMed ID: 23670856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The flexibility of P-glycoprotein for its poly-specific drug binding from molecular dynamics simulations.
    Liu M; Hou T; Feng Z; Li Y
    J Biomol Struct Dyn; 2013; 31(6):612-29. PubMed ID: 22888853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the three-dimensional structure of human P-glycoprotein in absence of ATP by computational techniques embodying crosslinking data: insight into the mechanism of ligand migration and binding sites.
    Vandevuer S; Van Bambeke F; Tulkens PM; Prévost M
    Proteins; 2006 May; 63(3):466-78. PubMed ID: 16463278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based interpretation of the mutagenesis database for the nucleotide binding domains of P-glycoprotein.
    Lawson J; O'Mara ML; Kerr ID
    Biochim Biophys Acta; 2008 Feb; 1778(2):376-91. PubMed ID: 18035039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular insight into conformational transmission of human P-glycoprotein.
    Chang SY; Liu FF; Dong XY; Sun Y
    J Chem Phys; 2013 Dec; 139(22):225102. PubMed ID: 24329094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational Insights into Allosteric Conformational Modulation of P-Glycoprotein by Substrate and Inhibitor Binding.
    Xing J; Huang S; Heng Y; Mei H; Pan X
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33353070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P glycoprotein and the mechanism of multidrug resistance.
    Váradi A; Szakács G; Bakos E; Sarkadi B
    Novartis Found Symp; 2002; 243():54-65; discussion 65-8, 180-5. PubMed ID: 11990782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insight into the molecular mechanism of P-glycoprotein mediated drug toxicity induced by bioflavonoids: an integrated computational approach.
    Wongrattanakamon P; Lee VS; Nimmanpipug P; Sirithunyalug B; Chansakaow S; Jiranusornkul S
    Toxicol Mech Methods; 2017 May; 27(4):253-271. PubMed ID: 27996361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains.
    Liu R; Sharom FJ
    Biochemistry; 1996 Sep; 35(36):11865-73. PubMed ID: 8794769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
    Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
    Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the inward- and outward-open homology models and ligand binding of human P-glycoprotein.
    Pajeva IK; Globisch C; Wiese M
    FEBS J; 2009 Dec; 276(23):7016-26. PubMed ID: 19878299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites.
    Acharya P; Tran TT; Polli JW; Ayrton A; Ellens H; Bentz J
    Biochemistry; 2006 Dec; 45(51):15505-19. PubMed ID: 17176072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein.
    Maki N; Moitra K; Silver C; Ghosh P; Chattopadhyay A; Dey S
    Biochemistry; 2006 Feb; 45(8):2739-51. PubMed ID: 16489767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesterol interaction with the daunorubicin binding site of P-glycoprotein.
    Wang E; Casciano CN; Clement RP; Johnson WW
    Biochem Biophys Res Commun; 2000 Oct; 276(3):909-16. PubMed ID: 11027568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein contacts and ligand binding in the inward-facing model of human P-glycoprotein.
    Pajeva IK; Hanl M; Wiese M
    ChemMedChem; 2013 May; 8(5):748-62. PubMed ID: 23564544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of putative binding sites of P-glycoprotein based on its homology model.
    Globisch C; Pajeva IK; Wiese M
    ChemMedChem; 2008 Feb; 3(2):280-95. PubMed ID: 18175303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket.
    Loo TW; Bartlett MC; Clarke DM
    Biochem J; 2006 Oct; 399(2):351-9. PubMed ID: 16813563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational analysis of the P-glycoprotein first intracellular loop and flanking transmembrane domains.
    Kwan T; Gros P
    Biochemistry; 1998 Mar; 37(10):3337-50. PubMed ID: 9521654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleotide binding to the multidrug resistance P-glycoprotein as studied by ESR spectroscopy.
    Delannoy S; Urbatsch IL; Tombline G; Senior AE; Vogel PD
    Biochemistry; 2005 Oct; 44(42):14010-9. PubMed ID: 16229490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of human P-glycoprotein transport substrates and inhibitors at the drug binding domain: Functional and molecular docking analyses.
    Kadioglu O; Saeed ME; Valoti M; Frosini M; Sgaragli G; Efferth T
    Biochem Pharmacol; 2016 Mar; 104():42-51. PubMed ID: 26807479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.